Contact without protection: high antenatal attendance, minimal hepatitis B testing in Nigerias mother-to-child prevention cascade -- how far from elimination?
Despite high antenatal care attendance in Nigeria, the mother-to-child hepatitis B elimination cascade is severely compromised by extremely low testing rates (12.3%) and suboptimal infant birth-dose coverage (55%), with the greatest gaps occurring in the poorest and highest-burden regions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Every year, millions of people around the world face a silent threat that begins before they take their first breath. This threat is the hepatitis B virus, a microscopic invader that attacks the liver. In many parts of the world, particularly in sub-Saharan Africa, this virus is a leading cause of liver cancer, a disease that often strikes decades after the initial infection. The story of this cancer usually starts in the earliest days of life. When a mother carries the virus, she can pass it to her baby during birth. If that baby becomes infected, the virus often settles in the liver for a lifetime, quietly damaging the organ until it fails or turns cancerous. However, this chain of events is not inevitable. Science has known for decades how to break it. A single shot of vaccine given to a newborn within hours of birth can stop the virus in its tracks. For mothers who carry a high amount of the virus, doctors can also give them medicine during pregnancy to lower the risk of passing it on. The solution exists, but it relies on a specific sequence of events: a pregnant woman must be tested to know her status, she must receive the result, and her baby must receive the vaccine immediately after birth. If any link in this chain breaks, the protection fails.
In Nigeria, a country that carries the largest burden of hepatitis B in Africa, researchers recently asked a critical question: how well is this chain of protection actually working? To find the answer, a team of scientists analyzed data from a massive national survey conducted in 2023 and 2024. They looked at the records of over 13,000 mothers who had given birth in the three years prior to the survey. The goal was to trace the path of prevention from the moment a woman visits a doctor for pregnancy care all the way to the moment her baby receives their first vaccine. This approach allowed them to see exactly where the system succeeds and where it falls apart, moving beyond simple statistics to understand the real-life journey of a mother and child.
The researchers found that the foundation for stopping this disease is already in place, but it is being used for the wrong purpose. They discovered that most Nigerian mothers, about 72 percent, do visit a clinic for antenatal care during their pregnancy. This is a strong starting point, as it means the healthcare system is already reaching the vast majority of women who need help. However, when the team looked at what happened during those visits, they found a startling gap. Only about 12 percent of these women were actually tested for hepatitis B. The system was seeing the mothers, but it was almost entirely missing the opportunity to check if they carried the virus. Among the small group of women who were tested, nearly all of them received their results, so the problem was not that they were left in the dark after the test. The failure happened right at the beginning, before the test was even ordered.
The situation becomes even more complex when looking at the babies. The study showed that about 55 percent of newborns received the crucial birth-dose vaccine. While this is better than the testing rate for mothers, it still leaves nearly half of all infants unprotected. The researchers noticed something important about how these vaccines were given: the decision to vaccinate a baby had almost nothing to do with whether the mother had been tested. Instead, whether a baby got the shot depended almost entirely on where the birth took place. Babies born in a health facility were much more likely to get the vaccine than those born at home. This revealed a disconnect in the healthcare system: the staff who vaccinate babies and the staff who care for pregnant women are working in parallel, rarely connecting the two. A mother's health status does not automatically trigger a specific action for her baby, even though that connection is vital for stopping the virus.
The study also highlighted that the problem is not spread evenly across the country. The gaps in protection are deepest in the regions where the virus is most common. In the North-West, an area with the highest rates of hepatitis B, testing for the virus was extremely rare, reaching only about 8 percent of pregnant women. In contrast, wealthier and more educated women in the southern parts of the country were far more likely to be tested and to have their babies vaccinated. The poorest families, those living in remote areas, and those with the least education were the least likely to receive any part of this protection. This creates a troubling reality where the people who need the system the most are the ones it fails the most. The researchers noted that the current approach is not just leaking protection; in many places, the protection system is barely built at all.
The findings suggest that the path to eliminating this preventable cancer does not require building a new system from scratch. The clinics are already there, and the mothers are already walking through their doors. The solution lies in using the existing contact to do something different. If the cost of testing were removed and the supplies made available, the same visits that are currently happening could become the moment of protection. The researchers emphasize that simply giving the vaccine to babies is not enough on its own, because it cannot fully protect the children of mothers with very high levels of the virus. Those mothers need to be identified and treated during pregnancy. By integrating the test into the routine care that almost every mother already receives, the country could turn a missed opportunity into a life-saving shield. The data makes it clear that the distance to eliminating hepatitis B is not a matter of distance or resources alone, but of using the tools already in hand to reach the people who need them most.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.